Lineage Cell Therapeutics
LCTX
80 hedge funds and large institutions have $113M invested in Lineage Cell Therapeutics in 2015 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 5 closing their positions.
508% more call options, than puts
Call options by funds: $3.08M | Put options by funds: $507K
240% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 5
42% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 19
16% more funds holding
Funds holding: 69 → 80 (+11)
0.72% more ownership
Funds ownership: 45.54% → 46.25% (+0.72%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
26% less capital invested
Capital invested by funds: $152M → $113M (-$38.9M)
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HF
76
Hoxton Financial
Shepherdstown,
West Virginia
| $1K | – | – | – |
|
|
PSI
77
Pinnacle Summer Investments
Fairfax,
Virginia
| $1K | – | – | – |
|
78
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $135 | -$12.2K | -3,138 | -6% |
|
|
CC
79
CQS Cayman
Camana Bay, Grand Cayman,
Cayman Islands
| – | -$683K | -170,191 | Closed |
|
|
MLICM
80
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$223K | -55,715 | Closed |
|
|
LP
81
LMR Partners
London,
United Kingdom
| – | -$91K | -22,658 | Closed |
|
|
PAM
82
Panagora Asset Management
Boston,
Massachusetts
| – | -$88K | -21,824 | Closed |
|
83
ProShare Advisors
Bethesda,
Maryland
| – | -$50K | -12,457 | Closed |
|
LCTX Hedge Fund Activity: Q2 2015 in Review
80 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2015, worth a combined $113M — down 26% from $152M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new LCTX positions and 5 closed out — a net gain of 12 holders — while 27 added to existing stakes and 19 trimmed.
The largest buyer was Destination Wealth Management, opening a new position worth an estimated $2.85M. The largest seller was Consonance Capital Management, cutting an estimated $4.55M.
- 80 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2015, up from 69 in Q1 2015.
- Funds reported $113M of Lineage Cell Therapeutics stock for Q2 2015, down 26% quarter-over-quarter.
- 17 funds opened new Lineage Cell Therapeutics positions in Q2 2015 and 5 closed out, a net change of +12 holders.
- The largest Lineage Cell Therapeutics buyer in Q2 2015 was Destination Wealth Management, an estimated $2.85M added.
- The largest Lineage Cell Therapeutics seller in Q2 2015 was Consonance Capital Management, an estimated $4.55M sold.
Based on aggregated 13F filings for Q2 2015.